Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Q&A
  • About Us
    • Our Coverage
    • Team

BioInvent International

23.00 SEK

-2.34 %

Less than 1K followers

BINV

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-2.34 %
-1.08 %
-21.77 %
-21.77 %
-18.29 %
-20.96 %
-22.82 %
-52.42 %
-97.59 %

BioInvent International is a biotechnology company focused on the development of innovative antibody therapies for cancer treatment. The company researches new treatments that can improve patient outcomes and quality of life. The company operates globally with a presence in international markets. BioInvent International was founded in 1983 and is headquartered in Lund.

Read more
Market cap
1.51B SEK
Turnover
439.04K SEK
Revenue
226.5M
EBIT %
-155.27 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
29/4
2026

Interim report Q1'26

29/4
2026

General meeting '26

27/8
2026

Interim report Q2'26

All
Webcasts
Press releases
ShowingAll content types
Regulatory press release3/31/2026, 9:45 AM

BioInvent International AB publicerar årsredovisningen för 2025

BioInvent International
Regulatory press release3/31/2026, 9:45 AM

BioInvent International AB publishes Annual Report 2025

BioInvent International
Press release3/26/2026, 2:27 PM

BioInvent får fas 3-milstolpe för HMI-115 vid endometrios

BioInvent International

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release3/26/2026, 2:27 PM

BioInvent achieves Phase 3 milestone for HMI-115 in endometriosis

BioInvent International
Regulatory press release3/24/2026, 7:00 AM

Kallelse till årsstämma i BioInvent International AB

BioInvent International
Regulatory press release3/24/2026, 7:00 AM

Notice to Annual General Meeting in BioInvent International AB

BioInvent International
Press release2/27/2026, 1:25 PM

Redeye: BioInvent (Q4 Update): Ovarian a New Value Driver

BioInvent International
BioInvent, Audiocast, Q4'25
Webcast2/26/2026, 1:00 PM

BioInvent, Audiocast, Q4'25

BioInvent International
Regulatory press release2/26/2026, 7:00 AM

BioInvent International AB: Bokslutskommuniké 1 januari – 31 december 2025

BioInvent International
Regulatory press release2/26/2026, 7:00 AM

BioInvent International AB: Year-end report January 1 – December 31, 2025

BioInvent International
Press release2/26/2026, 6:30 AM

Inbjudan till presentation av BioInvents bokslutskommuniké 2025

BioInvent International
Press release2/26/2026, 6:30 AM

Invitation to presentation of BioInvent’s Year-end report 2025

BioInvent International
Press release2/23/2026, 9:00 AM

BioInvent meddelar nominering av två nya styrelsemedlemmar inför årsstämman 2026

BioInvent International
Press release2/23/2026, 9:00 AM

BioInvent Announces Nomination of Two New Board Members Ahead of 2026 Annual General Meeting

BioInvent International
Press release1/9/2026, 6:57 AM

BioStock: BioInvent rapporterar lovande respons vid äggstockscancer

BioInvent International
Press release1/9/2026, 6:57 AM

BioStock: BioInvent reports promising response rate in ovarian cancer

BioInvent International
Regulatory press release1/5/2026, 6:30 AM

BioInvent rapporterar lovande data från pågående fas 2a-studie med BI-1808 och KEYTRUDA® (pembrolizumab) vid återfall av äggstockscancer

BioInvent International
Regulatory press release1/5/2026, 6:30 AM

BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA® (pembrolizumab) in Recurrent Ovarian Cancer

BioInvent International
Press release12/18/2025, 1:00 PM

BioInvent deltar i kommande investerarkonferenser

BioInvent International
Press release12/18/2025, 1:00 PM

BioInvent to Participate in Upcoming Investor Conference

BioInvent International
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.